

EDCTP Fact Sheet

EDCTP2 funding opportunities

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between sovereign States in Europe and sub-Saharan Africa. Now entering its second programme (EDCTP2), EDCTP aims to support collaborative research that accelerates the clinical development of new or improved interventions to prevent or treat HIV/AIDS, tuberculosis, malaria and neglected infectious diseases prevalent in sub-Saharan Africa. EDCTP2 will be implemented from 2014-2024 as part of the European Framework Programme for Research and Innovation, Horizon 2020.

The EDCTP Association currently consists of 13 European countries (Austria, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, UK) and 11 African countries (Cameroon, Congo, The Gambia, Ghana, Mozambique, Niger, Senegal, South Africa, Tanzania, Uganda and Zambia) as Participating States, with the possibility of additional countries joining at a later stage.

The European Union will provide a contribution of up to € 683 million for the EDCTP2 programme, to be matched by contributions from European EDCTP2 Participating States. Additionally, one of the EDCTP2 objectives is to leverage € 500 million from third parties.

Details on the activities to be funded under EDCTP2, including the Calls for Proposals, will be provided in annual work plans.




Scope of EDCTP2

EDCTP2 aims to contribute to the reduction of the social and economic burden of poverty-related diseases (PRDs) in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions for PRDs in partnership with sub-Saharan Africa.

PRDs covered by EDCTP2

In EDCTP2 PRDs include **HIV/AIDS, malaria, tuberculosis** and the following **neglected infectious diseases (NIDs)**: dengue; rabies; human African trypanosomiasis (sleeping sickness); Leishmaniasis; cysticercosis/taeniasis; dracunculiasis (guinea-worm disease); echinococcosis; foodborne trematodiasis; lymphatic filariasis; onchocerciasis (river blindness); schistosomiasis; soil-transmitted helminthiasis; Buruli ulcer; leprosy (Hansen disease); trachoma; yaws; diarrhoeal infections; lower respiratory infections; as well as emerging infectious diseases of particular relevance for Africa, such as Ebola.

The programme supports clinical trials and related research activities on PRDs, as well as capacity development for clinical trials and related research in sub-Saharan Africa. EDCTP2 supports all phases of clinical trials (phases I to IV) for new or improved medical interventions, as well as advanced testing and field validation of new diagnostic tools.



Third parties
(Private sector, PDPs, International Development Partners)

≥ € 683 M

≤ € 683 M

≥ € 500 M

IN-KIND/CASH

CASH

IN-KIND/CASH

PARTICIPATING STATES' INITIATED ACTIVITIES

EDCTP2 CALLS FOR PROPOSALS

- Administered by Participating States
- Selected and funded by Participating States
- Application of Participating States' funding rules

- Administered by EDCTP
- Funded by EDCTP, Participating States and third parties
- Application of Horizon 2020 participation rules

EDCTP2 supported activities

Multicentre clinical trials that are performed by research consortia involving both European and African research teams, with capacity building and networking elements integrated

Capacity support activities that strengthen the enabling environment for conducting clinical trials and clinical research

Fellowships that focus on the career development of individual researchers or clinical staff

The geographical focus of EDCTP2's activities is on sub-Saharan Africa.

Indicative EDCTP2 Calls for Proposals in 2014:

Diagnostic tools for PRDs

Scope of the Call for Proposals:

- Validation of clinical performance and/or implementation of new or improved diagnostic tools and technologies for PRDs, including as co-infections
- Advanced testing (e.g. evaluation and/or demonstration phase trials) or implementation studies in sub-Saharan Africa
- Planning for WHO endorsement and/or implementation of the diagnostic tools upon successful completion of the project
- Priority given to point-of-care diagnostics for use in resource-limited settings.

Open for applications	December 2014 (TBC)
Deadline for applications	March 2015 (TBC)
Call budget	€ 15 M
Maximum funding per grant	€ 3 M
Expected number of grants	4-8
Expected duration of grants	36-60 months
Minimum consortium requirement	Legal entities from: ≥ 2 EDCTP2 European Participating States; ≥ 1 sub-Saharan African country
Submission/evaluation process	Two-stage (letter of intent; full proposal)

Maximising the impact of EDCTP research

Scope of the Call for Proposals:

- Accelerate translation of research findings from EDCTP projects into policy and practice to maximise their public health impact in sub-Saharan Africa
- Translation and uptake of research findings into policy guidelines and defined changes in health systems or clinical practice; developing methodological tools for translation into public health programmes/practices; or optimising strategies for widespread adoption or research results
- Must include ≥ 1 legal entity previously supported through an EDCTP-funded grant directly related to the current application (multidisciplinary consortia encouraged).

Open for applications	December 2014 (TBC)
Deadline for applications	March 2015 (TBC)
Call budget	€ 3 M
Maximum funding per grant	€ 500,000 M
Expected number of grants	6-8
Expected duration of grants	24-36 months
Minimum consortium requirement	One legal entity
Submission/evaluation process	Single-stage (full proposal)

EDCTP-TDR Clinical Research & Development Fellowships

Scope of the Call for Proposals:

- Joint initiative with WHO-TDR
- Support researchers and key clinical trial research team members from low and middle income countries (LMICs) to acquire clinical research and development skills through placements in pharmaceutical companies and PDPs
- Targets junior to mid-career researchers or clinical staff employed in LMICs and working on activities in the scope of EDCTP and TDR
- EDCTP funds will support applicants from sub-Saharan Africa placed at pharmaceutical companies in Europe.

Open for applications	31 October 2014
Deadline for applications	30 January 2015
Eligible costs	Limited to stipend, educational materials, travel and visa, attendance to meetings, health insurance and reintegration costs
Expected number of grants	25 (10 by EDCTP; 15 by WHO-TDR)
Expected duration of grants	6-24 months
Minimum consortium requirement for EDCTP grants	Legal entities from: 1 sub-Saharan African country
Submission/evaluation process	Single-stage (full proposal)

Calls for Proposals 2015: indicative topics

- Treatment and clinical management trials
- Strategic trials with major cofunding (≥ € 10 M budget with ≥ 50% cofunding secured)
- Regional Networks
- Ethics and regulatory capacities
- Fellowships
 - Senior fellowships
 - Career development fellowships
 - EDCTP-TDR clinical research and development fellowships.

Who can participate in EDCTP2 activities?

Legal entities from anywhere in the world can normally participate in EDCTP2 activities, either as a coordinator or as a collaborator, as long as the minimum eligibility criteria are fulfilled as specified in the Call for Proposals.

Who can receive EDCTP2 funding?

Legal entities established in sub-Saharan African countries, in EU Member States, in overseas countries and territories linked to the EU Member States, or in Countries Associated to Horizon 2020 are automatically eligible to receive EDCTP2 funding. Within these eligible countries, any type of legal entity, public or private, is eligible to receive funding.

Is cofunding required?

For the majority of EDCTP2 Calls for Proposals, EDCTP funds 100% of direct costs (with additional 25% for covering indirect costs) without any requirement for cofunding from other funders.

For more information:

EDCTP Europe office
T: +31 70 344 0880
F: +31 70 344 0899

EDCTP Africa office
T: +27 21 938 0819
F: +27 21 938 0569

E: info@edctp.org
I: www.edctp.org